Sotyktu (Deucravacitinib) Patent Expiration, LOE Window & CMS Spending

Sotyktu (Deucravacitinib) by Bristol Myers Squibb: FDA Orange Book core substance LOE 2033-11-07 (last listed 2043-02-11), 0 AB generics, $88.9M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBristol Myers Squibb
FDA Application & PathwayN214958 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2033-11-07
Last Listed Patent or Exclusivity Date2043-02-11
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$88.9M
2024 Medicare Part D Spend$62.2M
2024 Medicaid Spend$26.7M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.